SLC37A3 Activators
SLC37A3 Activators encompass a selection of chemical compounds that indirectly bolster the operational activity of SLC37A3, a protein involved in glucose transport and homeostasis. Compounds such as Forskolin, Isoquinoline, and Glucagon-like peptide 1 (GLP-1) elevate intracellular cAMP levels and subsequently activate PKA, which can phosphorylate transport-related proteins, thereby potentially enhancing the activity of SLC37A3. Similarly, Ciglitazone and Rosiglitazone, as PPARγ agonists, and Dexamethasone, through glucocorticoid receptor activation, modulate the expression of genes involved in glucose metabolism, which could lead to an indirect upregulation of SLC37A3 function. Insulin, through the PI3K/Akt pathway, and Metformin and AICAR, via AMPK activation, exert regulatory effects on glucose metabolism that may encompass the facilitation of SLC37A3 activity as part of a broader cellular response to maintain glucose equilibrium.
Additionally, the direct interaction of Glucose with SLC37A3 could allosterically activate the transporter, whereas 2-Deoxy-D-glucose, by inhibitingglycolysis, may provoke a compensatory mechanism that enhances SLC37A3 function. Lastly, Chlorogenic acid, with its influence on glucose metabolism, could potentially modify the activity of glucose transport systems, including that of SLC37A3. Collectively, these activators function through various biochemical pathways to augment the function of SLC37A3, ensuring efficient management of glucose within the cellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin stimulates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate and activate various proteins, including transporters. As SLC37A3 is a phosphate-linked glucose-phosphate antiporter, PKA-mediated phosphorylation could enhance its activity. | ||||||
Ciglitazone | 74772-77-3 | sc-200902 sc-200902A | 5 mg 25 mg | $102.00 $420.00 | 10 | |
Ciglitazone is a PPARγ agonist that upon activation can lead to the transcription of genes involved in glucose metabolism. Activation of PPARγ may upregulate the expression of SLC37A3, as it is involved in glucose homeostasis, thereby indirectly enhancing its functional activity. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone acts as a glucocorticoid receptor agonist, which upon activation can modulate the expression of genes involved in glucose metabolism. It could potentially upregulate SLC37A3 activity by influencing the transcription of genes that regulate glucose homeostasis. | ||||||
Isoquinoline | 119-65-3 | sc-255224 sc-255224A | 5 g 100 g | $26.00 $58.00 | ||
Isoquinoline can inhibit phosphodiesterase, thereby preventing the breakdown of cAMP. By maintaining high levels of cAMP, it indirectly supports the activation of PKA, which could lead to the phosphorylation and enhanced activity of SLC37A3. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin activates the PI3K/Akt signaling pathway, which plays a significant role in glucose uptake and metabolism. Although not directly linked, this pathway could upregulate SLC37A3 function as part of the broader regulation of glucose homeostasis. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMP-activated protein kinase (AMPK), which in turn can regulate glucose metabolism. AMPK activation may indirectly stimulate SLC37A3 function within the cellular glucose management system. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone is another PPARγ agonist that can modulate the transcription of genes associated with glucose metabolism. Its activation could result in an increased functional activity of SLC37A3 by enhancing glucose transport pathways. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR is an AMPK agonist that can activate AMPK, leading to altered metabolism and glucose homeostasis. It may indirectly increase the activity of SLC37A3 through its role in regulating glucose transport. | ||||||
D(+)Glucose, Anhydrous | 50-99-7 | sc-211203 sc-211203B sc-211203A | 250 g 5 kg 1 kg | $37.00 $194.00 $64.00 | 5 | |
Glucose can allosterically activate glucose transporters and related proteins through its binding and transport. It could potentially enhance the functional activity of SLC37A3 by directly interacting as a substrate for the transporter. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose acts as a glucose analog and inhibitor of glycolysis, which could lead to the compensatory activation of glucose transport pathways, potentially enhancing the activity of SLC37A3. | ||||||